Botulism

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence

Saturday, May 23, 2020 - 6:00am

The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.

Key Points: 
  • The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.
  • Symptom recurrence significantly impacted patients quality of life, including sleep, relationships, performance of daily tasks and working lives.
  • Eligible participants were over 18 years old and had (or cared for someone with) spasticity or cervical dystonia (CD) treated with BoNT-A for at least one year.
  • How do patients with cervical dystonia (CD) experience their botulinum neurotoxin type a (BoNT-A) treatment cycle: results from an international online survey.

Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020

Thursday, April 30, 2020 - 9:05pm

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will release first quarter 2020 financial results on Thursday, May 7, 2020 after the close of market.

Key Points: 
  • Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will release first quarter 2020 financial results on Thursday, May 7, 2020 after the close of market.
  • A replay of the call will be available beginning May 7, 2020 at 4:30 p.m. PT/7:30 p.m.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.

Pipeline Review on Botulism, H1 2020 - ResearchAndMarkets.com

Wednesday, April 29, 2020 - 10:45am

The "Botulism - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Botulism - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The pipeline guide reviews pipeline therapeutics for Botulism (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • Formulate corrective measures for pipeline projects by understanding Botulism (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Revance to Participate in the Barclays Global Healthcare Conference 2020

Tuesday, March 3, 2020 - 9:05pm

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the company will participate in the Barclays Global Healthcare Conference 2020, in Miami, FL.

Key Points: 
  • Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the company will participate in the Barclays Global Healthcare Conference 2020, in Miami, FL.
  • Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com .
  • Revance has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.

Botulinum Toxin and Cosmetic Fillers (Children) Bill 2019-20

Friday, February 7, 2020 - 12:02am

House of Commons Library

Key Points: 
  • House of Commons Library

    The Botulinum Toxin and Cosmetic Fillers (Children) Bill 2019-20 was introduced by Laura Trott MP following the Private Members' Bills Ballot on 9 January 2020.

  • First reading took place on 5 February 2020 and the Bill's second reading is due on 15 May 2020.
  • Bill summary

    A Bill to make provision about the administration to persons under the age of 18 of botulinum toxin and of other substances for cosmetic purposes; and for connected purposes.

  • The Public Bill Office (PBO) supports public bill committees.

Revance Announces U.S. FDA Acceptance of Biologics License Application (BLA) for DAXI to Treat Glabellar (Frown) Lines

Thursday, February 6, 2020 - 1:00pm

The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.

Key Points: 
  • The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
  • The patient experience has remained largely unchanged since botulinum toxin type A treatments were first introduced over 30 years ago.
  • Revance has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    BOTOX is a registered trademark of Allergan, Inc.

Botulinum Toxin and Cosmetic Fillers (Children)

Thursday, February 6, 2020 - 1:00pm

Latest news on the Botulinum Toxin and Cosmetic Fillers (Children) Bill 2019-20

Key Points: 
  • Latest news on the Botulinum Toxin and Cosmetic Fillers (Children) Bill 2019-20

    The next stage for this Bill, Second reading,is scheduled to take placeon Friday 15 May 2020.

  • This is a Private Members'Billand waspresented to Parliament on Wednesday 5 February 2020 through the ballot procedure.
  • If the text of the Bill is not yet available, please contact its sponsor, Laura Trott MP, for more information.
  • Summary of the Botulinum Toxin and Cosmetic Fillers (Children) Bill 2019-20

    A Bill to make provision about the administration to persons under the age of 18 of botulinum toxin and of other substances for cosmetic purposes; and for connected purposes.

ALPHAEON Corporation Completes Reorganization to Simplify its Corporate Structure

Friday, January 10, 2020 - 9:29pm

ALPHAEON Corporation (ALPHAEON), announced today that it has completed a reorganization to simplify its corporate structure.

Key Points: 
  • ALPHAEON Corporation (ALPHAEON), announced today that it has completed a reorganization to simplify its corporate structure.
  • ALPHAEON has been renamed AEON Biopharma, Inc. (AEON), which will now focus on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, as a therapeutic application for debilitating medical conditions.
  • We continue to have a positive outlook on the long-term potential of the position held in Evolus for our stockholders.
  • AEON Biopharma, Inc. (previously known as ALPHAEON Corporation) focuses on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, for debilitating medical conditions.

Ipsen: Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy

Monday, January 6, 2020 - 6:00am

Having a therapeutic option approved for both upper and lower limb indications creates a real benefit for the patient as it allows a holistic treatment approach for any patients with multi-focal spasticity.

Key Points: 
  • Having a therapeutic option approved for both upper and lower limb indications creates a real benefit for the patient as it allows a holistic treatment approach for any patients with multi-focal spasticity.
  • As of 31 December 2018, Dysport had marketing authorization in more than 85 countries for therapeutic treatment indications and more than 30 years of clinical experience.
  • For the treatment of focal spasticity, Dysport can also be administered by healthcare professionals having received appropriate training and qualification in accordance with national guidelines (e.g.
  • The group develops and commercializes innovative medicines in three key therapeutic areas Oncology, Neuroscience and Rare Diseases.

Global Botulinum Toxin Market Size, Trends and Forecasts Report 2019-2023 - Focus on US, Europe, Japan, Asia (excluding Japan), Korea and China

Monday, December 9, 2019 - 6:15pm

DUBLIN, Dec. 9, 2019 /PRNewswire/ -- The "Global Botulinum Toxin Market: Size, Trends and Forecasts (2019-2023 Edition)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 9, 2019 /PRNewswire/ -- The "Global Botulinum Toxin Market: Size, Trends and Forecasts (2019-2023 Edition)" report has been added to ResearchAndMarkets.com's offering.
  • Global Botulinum Toxin Market: Size, Trends and Forecasts (2019-2023 Edition) provides an in-depth analysis of the global botulinum toxin market with detailed analysis of the actual and the expected market size along with the market size of each market segment on the basis of application, products as well as regional.
  • The report provides a detailed regional analysis of the US, Europe, Japan, Asia (excluding Japan), Korea and China for the botulinum toxin market.
  • Regional analysis includes the market share of each region or country and the actual and forecasted market size of the botulinum toxin market along with the market segments of the aforementioned regions.